| Interventions |
Intervention1: Oral Tofacitinib: Tofacitinib is an oral JAK 1/3 inhibitor which has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease and has been used to treat other autoimmune disease such as alopecia areata and vitiligo and atopic dermatitis. Tofacitinib suppresses the activity of cytokines, predominantly IFN-gamma, IL-22, and tumor necrosis factor alpha which may be beneficial in allergic contact dermatitis. A few case reports have shown the role of JAK inhibitors in managing allergic contact dermatitis in humans. In a study by Baltazar et al, oral abrocitinib resulted in complete resolution of occupational ABCD to Compositae in a 37 year old man in whom topical corticosteroids and dupilumab had failed. Similarly, a 57 year old female who did not respond to allergen avoidance and therapeutic agents including corticosteroids, topical calcineurin inhibitors, and azathioprine, showed near-complete resolution of chronic Parthenium-induced ABCD with oral tofacitinib administered at a dose of 5 mg twice daily for four weeks. JAK inhibitors seem to be promising agents in the management of airborne contact dermatitis, however there are no studies to determine their therapeutic role and safety in this disease. Therefore, we plan to study the effectiveness and safety of oral tofacitinib in patients with Parthenium dermatitis and its impact on patch test positivity in these patients. In this study, patients will be given oral tofacitinib at a dose of 10 mg/day(5 mg twice daily) for a period of 12 weeks or till complete healing of dermatitis, whichever is earlier. Topical corticosteroids (clobetasol propionate 0.05% w/w) and oral antihistamines(levocetirizine 10 mg) will also be given for symptomatic control of the di |